The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer
Official Title: A Clinical Study of Aliya™ Pulsed Electric Fields (PEF) Delivered Prior to Standard of Care Treatment for Advanced Cancer
Study ID: NCT05890872
Brief Summary: The goal of this clinical trial is to evaluate safety of delivering Aliya PEF in patients with metastatic cancer within the lungs or stage IV non-small cell lung cancer (NSCLC) who are treatment-naïve and indicated for first-line standard of care (SOC) cancer therapy.
Detailed Description: The Aliya Treatment System is designed to deliver therapeutic PEF energy to target tissues, via either a percutaneous or bronchoscopic approach. In order to evaluate the therapeutic potential of PEF delivered via the Aliya Treatment System as an interventional treatment, this clinical trial will evaluate the safety of delivering Aliya PEF in non-surgical advanced stage disease treatment-naïve patients indicated for diagnostic biopsy and first line (1L) standard of care (SOC) therapy. Additionally, this study will examine the safety of adding PEF treatment to the care pathway for patients with metastatic cancer to the lung or stage IV NSCLC and further assess the potential immune modulation and treatment effect of PEF for providing benefit to oncological patients, as outlined below.
Minimum Age: 22 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Mayo Clinic, Jacksonville, Florida, United States
Mayo Clinic Rochester, Rochester, Minnesota, United States
Weill Cornell Medicine | New York-Presbyterian, New York, New York, United States
FirstHealth of the Carolinas, Inc., Pinehurst, North Carolina, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Name: William Krimsky, MD
Affiliation: Chief Medical Officer
Role: STUDY_CHAIR